Gefitinib Teva 250 mg
As listed in the register: Gefitinib Teva 250 mg, filmomhulde tabletten
250 mg · filmomhulde tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Gefitinib
- Made by
- Teva B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Gefitinib). It describes the substance, not this exact product.
The epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells and plays a role in the processes of cell growth and proliferation.
Some EGFR activating mutations (exon 19 deletion or exon 21 point mutation L858R) within NSCLC cells have been identified as contributing to the promotion of tumor cell growth, blocking of apoptosis, increasing the production of angiogenic factors and facilitating the processes of metastasis.
Metabolism and Elimination Gefitinib undergoes extensive hepatic metabolism in humans, predominantly by CYP3A4.
Food does not alter gefitinib bioavailability to a clinically meaningful extent.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-03-10
Safety of the active substance
From the US prescribing label for the same active substance (Gefitinib). It describes the substance, not this exact product.
The most frequent adverse reactions in Study 3 (incidence of >20% and greater than placebo) reported in gefitinib tablets-treated patients were skin reactions (47%) and diarrhea (29%).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States5 matching products
European UnionNo exact match for this strength and form
Spain10 matching products
- GEFITINIB ACCORD 250 mg · comprimido recubierto con película
- GEFITINIB ARISTO 250 mg · comprimido recubierto con película
- GEFITINIB CIPLA 250 mg · comprimido recubierto con película
- GEFITINIB EUGIA 250 mg · comprimido recubierto con película
- GEFITINIB GENTHON 250 mg · comprimido recubierto con película
- GEFITINIB MYLAN 250 mg · comprimido recubierto con película
- GEFITINIB QILU 250 mg · comprimido recubierto con película
- GEFITINIB SALA 250 mg · comprimido recubierto con película
Canada6 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Teva B.V. |
|---|---|
| Active substance | Gefitinib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 250 mg |
| Form | filmomhulde tablet |
| Classification | L01EB01 · Cancer treatments and immune-system medicines |
| Route | oraal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Gefitinib Teva 250 mg, filmomhulde tabletten |
| RVG | 121854 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.